Comparative Analysis of Outcomes for Patients With Advanced Renal Cell Carcinoma: Immuno-Oncology Era<i>Versus</i>Tyrosine Kinase Inhibitor Era in the IMDC Favorable-risk Group
The implementation of IO therapies has enhanced tumor response rates among patients within the IMDC favorable-risk group, although extended follow-up is necessary to ascertain any survival benefits.
Authors
- Toshio Takagi (ORCID: https://orcid.org/0000-0003-1775-0943)
- Koichi Nishimura (ORCID: https://orcid.org/0000-0003-0651-7484)
- Kazuhiko Yoshida (ORCID: https://orcid.org/0000-0002-3834-0153)
- Tsunenori Kondo (ORCID: https://orcid.org/0000-0003-2228-4086)
- Hironori Fukuda (ORCID: https://orcid.org/0009-0008-3009-0146)
- Hiroki Ishihara (ORCID: https://orcid.org/0000-0002-5146-656X)
- Yasunobu Hashimoto
- Yuki Nemoto (ORCID: https://orcid.org/0000-0003-4290-0595)
- Hiroaki Shimmura
- Junpei Iizuka
- Shinsuke Mizoguchi
Institutions
- Jyoban Hospital of Tokiwa Foundation (JP)
- Tokyo Women's Medical University Adachi Medical Center (JP)
- Tokyo Women's Medical University (JP)
- Saiseikai Fukuoka General Hospital (JP)
- Saiseikai Ibaraki Hospital (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2025-03-28
- DOI
- https://doi.org/10.21873/anticanres.17545
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00